1. Home
  2. MMA vs GNPX Comparison

MMA vs GNPX Comparison

Compare MMA & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMA

Alta Global Group Limited

HOLD

Current Price

$0.56

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.84

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
GNPX
Founded
2013
2009
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.8M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
MMA
GNPX
Price
$0.56
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
370.8K
723.0K
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.14
52 Week High
$2.00
$12.97

Technical Indicators

Market Signals
Indicator
MMA
GNPX
Relative Strength Index (RSI) 49.30 28.01
Support Level $0.35 $0.15
Resistance Level $0.74 $2.12
Average True Range (ATR) 0.06 0.06
MACD -0.01 0.02
Stochastic Oscillator 31.04 10.91

Price Performance

Historical Comparison
MMA
GNPX

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: